[
  {
    "id": "2026072639744200709",
    "text": "$VIR ğŸš€ Massive AH breakout on oncology + partnership catalyst.  Up 60% AH \nğŸ”¹ Vir Biotechnology = immunology + oncology innovator (PRO-XTENÂ® masked T-cell engagers) ğŸ§¬\nğŸ”¹ Global strategic collaboration with Astellas to advance PSMA-targeted VIR-5500 in prostate cancer ğŸ¤ğŸ”¥\nğŸ”¹ Updated Phase 1 data: dose-dependent anti-tumor activity + favorable safety in mCRPC ğŸ“Š\nğŸ”¹ Expansion cohorts launching Q2 â€˜26 â†’ Phase 3 in 2027 roadmap ğŸ—ºï¸\nğŸ”¹ Hepatitis Delta combo: 88% undetectable HDV RNA at Week 96 in Phase 2 ğŸ¦ \nğŸ”¹ Strong balance sheet: $781.6M cash & investments ğŸ’°\nğŸ”¹ Shares outstanding: ~100M ğŸ”¢\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 23:12:14 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 2,
    "conversationId": "2026072639744200709",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026048902198370603",
    "text": "$GIPR ğŸš€ After-hours spike on high-stakes listing catalyst.  Up 30% AH \nğŸ”¹ Generation Income Properties = net lease REIT (single-tenant, investment-grade focus) ğŸ¢\nğŸ”¹ Company hit with Nasdaq delisting denial due to equity requirement issues âš ï¸\nğŸ”¹ Management says theyâ€™ll request a Nasdaq Hearings Panel â€” typically stays delisting during the process ğŸ§¾\nğŸ”¹ This is a binary headline setup: appeal outcome + recapitalization path = huge volatility ğŸ¢\nğŸ”¹ Shares outstanding: ~5.44M ğŸ”¢\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 21:37:55 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026048902198370603",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026046150709534887",
    "text": "$SILO ğŸš€ After-hours rip on shareholder-friendly move.  Up 46% AH \nğŸ”¹ Silo Pharma = developmental-stage biopharma merging traditional therapeutics + psychedelic research ğŸ§ ğŸ§¬\nğŸ”¹ Board just authorized a share repurchase program â€” up to $1M of common stock ğŸ§¾ğŸ”¥\nğŸ”¹ Buybacks at micro-cap levels = loud signal management thinks the stock is mispriced ğŸ‘€\nğŸ”¹ Optionality stack: PTSD + chronic pain + CNS pipeline catalysts still in play âš¡ï¸\nğŸ”¹ Shares outstanding: ~13.3M ğŸ”¢\nOpinions are my own. Not a solicitation to buy or sell.",
    "createdAt": "Mon Feb 23 21:26:59 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026046150709534887",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026043668616905067",
    "text": "$MYGN ğŸš€ After-hours breakout on execution + 2026 roadmap.  Up 21% AH \nğŸ”¹ Myriad = molecular diagnostics + precision medicine (oncology + mental health testing) ğŸ§¬\nğŸ”¹ Q4 rev $209.8M (better underlying growth ex-headwinds) ğŸ“ˆ\nğŸ”¹ FY25 rev $824.5M; reaffirmed 2026 guidance âœ…\nğŸ”¹ Volume drivers: Prolaris +12%, Hereditary cancer +9%, GeneSight +9% YoY ğŸ§ ğŸ©º\nğŸ”¹ GM 70% | Adj EPS $0.04 | Adj EBITDA $14.3M ğŸ’ª\nğŸ”¹ 2026 â€œproduct cycleâ€ catalyst stack: Precise MRD (alpha launch March), AI Prolaris (Q2), FirstGene prenatal (2H) ğŸš€\nğŸ”¹ Shares outstanding: ~92.5M ğŸ”¢\nNot a recommendation. Trade at your own risk.",
    "createdAt": "Mon Feb 23 21:17:07 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026043668616905067",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026043241603239980",
    "text": "$SGHC ğŸš€ After-hours rip on a monster FY25 print up 12%\nğŸ”¹ Super Group = parent of Betway (sportsbook) + Spin (online casino) ğŸ°ğŸŸï¸\nğŸ”¹ FY25 revenue: $2.2B | Q4 revenue: $578.3M ğŸ“Š\nğŸ”¹ FY25 profit before tax: $355.9M | Q4: $95.1M ğŸ’°\nğŸ”¹ FY25 Adj. EBITDA: $559.5M | Q4: $139.0M âš¡ï¸\nğŸ”¹ Cash: $513.2M (12/31/25) ğŸ§±\nğŸ”¹ Dividend floor raised to $0.05/qtr (from $0.04) ğŸ§¾ğŸ”¥\nğŸ”¹ Shares outstanding: ~506M ğŸ”¢\nğŸ”¹ Annual financial statements coming early April 2026 ğŸ—“ï¸\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 21:15:25 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026043241603239980",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026042719177412612",
    "text": "$BHAT ğŸš€ After-hours pop as traders react to the latest catalysts\nğŸ”¹ Blue Hat = China/Malaysia commodity + precious metals operator (gold, diamonds, jewelry) ğŸª™ğŸ’\nğŸ”¹ Fresh headline: underwritten public offering priced (new units + warrants) â€” big liquidity/dilution event driving volatility ğŸ’¥\nğŸ”¹ Company also pushing the narrative: expanding gold trading business into 2026 ğŸ“ˆğŸŸ¡\nğŸ”¹ This is a headline-driven ticker â€” expect fast swings around filings + financing updates âš ï¸\nğŸ”¹ Shares outstanding: ~36.9M ğŸ”¢\nOpinions are my own. Not a solicitation to buy or sell.",
    "createdAt": "Mon Feb 23 21:13:20 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 3,
    "conversationId": "2026042719177412612",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026040931078561851",
    "text": "$EZRA ğŸš€ After-hours strength on fresh catalyst up 17%\nğŸ”¹ Reliance Global Group = insurance + InsurTech (RELI Exchange) building recurring premium + distribution ğŸ“²\nğŸ”¹ Just closed the Enquantum transaction â€” stepping into post-quantum cybersecurity ğŸ”âš¡ï¸\nğŸ”¹ Positioning for a multi-year â€œcrypto upgrade cycleâ€ as quantum risk goes mainstream ğŸ§ ğŸŒ\nğŸ”¹ Bigger picture: EZRA International Group strategy = acquiring/control stakes in high-tech plays ğŸ§©ğŸ“ˆ\nğŸ”¹ Shares outstanding: ~10.7M ğŸ”¢\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 21:06:14 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026040931078561851",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026017866105954393",
    "text": "$BATL â€” added the dip ğŸ›¢ï¸ğŸ”¥\nğŸ”¹ What they do: Permian (Delaware Basin) oil & gas producer â€” pure beta to crude\nğŸ”¹ Company-side catalyst: New gas treating deal with a large-cap midstream partner + ops improvements after the prior treating outage âœ…\nğŸ”¹ Balance sheet angle: Announced sale of West Quito Draw assets (~$62.6M) â€” proceeds aimed at debt paydown + flexibility ğŸ’°\nğŸ”¹ Macro kicker (my view): If Middle East risk escalates, oil can spike fast â†’ high-beta E&Ps like $BATL can rip ğŸ“ˆ\nğŸ”¹ Shares outstanding: ~16.46M ğŸ”¢\nRetail + tight share count = this can move way more than people expect ğŸ‘€âš¡ï¸\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 19:34:35 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 6,
    "conversationId": "2026017866105954393",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2026014372578070761",
    "text": "$NCI +44% â€” microcap apparel name going vertical ğŸ“ˆğŸ§µ\nğŸ”¹ What they do: One-stop apparel solutions (design, sourcing, manufacturing + supply chain)\nğŸ”¹ Todayâ€™s catalyst: Closed an ~$8.1M public offering (fresh capital headline) ğŸ’¥\nğŸ”¹ Why it matters: More runway for growth + working capital = traders front-run the â€œturnaround/expansionâ€ story ğŸš€\nğŸ”¹ Retail setup: Tight float can snowball fast when volume hits âš¡ï¸\nğŸ”¹ Shares outstanding: ~20.3M | Float: ~3.8M ğŸ”¢\nEyes on $NCI â€” if volume stays elevated, retail can keep pressing this ğŸ‘€ğŸ”¥\nOpinions are my own. Not a solicitation to buy or sell.",
    "createdAt": "Mon Feb 23 19:20:42 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2026014372578070761",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025997782931349798",
    "text": "$GFAI +25% â€” buyback headline = retail magnet ğŸ§²ğŸš€\nğŸ”¹ What they do: AI + robotics + secured logistics (cash-in-transit, cash management, retail automation) ğŸ¤–ğŸ’¼\nğŸ”¹ Todayâ€™s catalyst: Board approved a share repurchase program up to $5M ğŸ’¥\nğŸ”¹ Why it matters: Buyback signal + microcap liquidity can turbocharge momentum when volume hits ğŸ“ˆ\nğŸ”¹ Retail setup: This name moves FAST when the crowd shows up ğŸ”¥\nğŸ”¹ Shares outstanding: ~21.82M ğŸ”¢\nEyes on $GFAI â€” if volume holds, retail can absolutely push the next leg ğŸ‘€âš¡ï¸\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 18:14:47 +0000 2026",
    "replyCount": 0,
    "retweetCount": 1,
    "likeCount": 2,
    "conversationId": "2025997782931349798",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025995997780881709",
    "text": "$KLTO +27% â€” biotech IP catalyst hitting the tape ğŸ§¬ğŸš€\nğŸ”¹ What they do: Gene/cell therapy platform built around the â€œanti-agingâ€ secreted Klotho (s-KL) protein targeting neurodegenerative + aging-related diseases\nğŸ”¹ Todayâ€™s catalyst: Australia accepted 18 patent claims covering composition + use of human secreted Klotho (s-KL) â€” strengthening the IP moat ğŸŒğŸ›¡ï¸\nğŸ”¹ Why it matters: More IP = more leverage for partnerships, licensing, and future clinical/regulatory pathways ğŸ“ˆ\nğŸ”¹ Retail setup: Microcap + headline-driven volume can snowball fast when momentum traders pile in ğŸ”¥\nğŸ”¹ Shares outstanding: ~73.5M ğŸ”¢\nEyes on $KLTO â€” if volume stays elevated, this can keep running ğŸ‘€âš¡ï¸\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 18:07:41 +0000 2026",
    "replyCount": 0,
    "retweetCount": 1,
    "likeCount": 2,
    "conversationId": "2025995997780881709",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025995587271954487",
    "text": "$GNPX +26% â€” patent + platform momentum ripping today ğŸ§¬ğŸš€\nğŸ”¹ What they do: Clinical-stage gene therapy company targeting cancer + diabetes (non-viral delivery platform)\nğŸ”¹ Todayâ€™s catalyst: New IP wins â€” strengthening the patent moat around ReqorsaÂ® combos with immunotherapies ğŸŒğŸ›¡ï¸\nğŸ”¹ Why it matters: More IP protection = more leverage for partnering + trial pathway confidence ğŸ“ˆ\nğŸ”¹ Pipeline focus: ReqorsaÂ® lung cancer programs + GPX-002 diabetes gene therapy progress ğŸ”¥\nğŸ”¹ Shares outstanding: ~2.32M ğŸ”¢\nEyes on $GNPX â€” if volume sticks, this kind of float can get wild ğŸ‘€âš¡ï¸\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 18:06:03 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2025995587271954487",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025946647209849090",
    "text": "$YMAT +35% â€” microcap composite play waking up ğŸš€ğŸ§µ\nğŸ”¹ What they do: Carbon fiber + composite solutions (sports gear, auto parts, healthcare products, resin systems) ğŸ§¬\nğŸ”¹ Todayâ€™s catalyst: Exclusive global distribution agreement with Patriot Green Energy Technology (PSSB) ğŸŒğŸ¤\nğŸ”¹ Why it matters: Distribution leverage = faster commercial reach + new demand channels (especially for advanced materials) ğŸ“ˆ\nğŸ”¹ Retail angle: Low float vibes â€” volume can snowball fast when the story catches ğŸ”¥\nğŸ”¹ Shares outstanding: ~17.2M ğŸ”¢\nEyes on $YMAT â€” if this holds with volume, retail can absolutely drive the next leg ğŸ‘€ğŸš€\nNot a recommendation. Trade at your own risk.",
    "createdAt": "Mon Feb 23 14:51:35 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2025946647209849090",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025945167883047290",
    "text": "$BATL +9% â€” war-risk headlines = oil squeeze narrative ğŸ”¥ğŸ›¢ï¸\nğŸ”¹ What they do: Permian-focused oil & gas E&P (cash flow tied straight to crude moves)\nğŸ”¹ Todayâ€™s driver: Middle East / Iran escalation fears pushing oil higher â†’ energy names catching bids ğŸ“ˆ\nğŸ”¹ Retail setup: Tiny share count = moves can get exaggerated fast when volume hits âš¡ï¸\nğŸ”¹ Shares outstanding: ~16.46M ğŸ”¢\nğŸ”¹ What Iâ€™m watching: sustained volume + hold of gains into close (thatâ€™s when squeezes get real) ğŸ‘€\nIf retail piles in, $BATL can rip harder than people expect ğŸš€\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 14:45:42 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 3,
    "conversationId": "2025945167883047290",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025943517609021948",
    "text": "$IBRX +19% â€” biotech momentum is back ğŸš€ğŸ§¬\nğŸ”¹ What they do: Commercial-stage immunotherapy company focused on cancer + infectious disease platforms\nğŸ”¹ Todayâ€™s catalyst: EU authorization for ANKTIVAÂ® + BCG in non-muscle invasive bladder cancer (CIS) â€” expanding access across 33 countries ğŸŒ\nğŸ”¹ More upside fuel: International rollout building (new Saudi commercialization partnership to launch ANKTIVA) ğŸ¤\nğŸ”¹ Why it matters: Label/access expansion = bigger TAM + faster revenue ramp potential ğŸ“ˆ\nğŸ”¹ Shares outstanding: ~945M ğŸ”¢\nEyes on $IBRX â€” strength like this usually pulls in a new wave of momentum traders ğŸ‘€ğŸ”¥\nOpinions are my own. Not a solicitation to buy or sell.",
    "createdAt": "Mon Feb 23 14:39:09 +0000 2026",
    "replyCount": 2,
    "retweetCount": 1,
    "likeCount": 7,
    "conversationId": "2025943517609021948",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025938554791043460",
    "text": "$ALUR â€“ +43% premarket ğŸ‘€ğŸš€\nğŸ”¹ Weight-loss device + digital care platform (Smart Capsule + virtual care) ğŸ§ ğŸ“²\nğŸ”¹ Catalyst: prelim Q4/FY results showing QoQ revenue growth + meaningful opex/operating loss improvement as the 2025 pivot starts to show ğŸ“ˆâœ…\nğŸ”¹ Also leaning into the GLP-1 wave: combo approach (Smart Capsule + tirzepatide access via partners) getting traction in markets outside the U.S. ğŸ’‰ğŸ¤\nğŸ”¹ Shares outstanding: ~7.77M ğŸ”¢\nğŸ”¹ Low-float = moves get exaggerated fastâ€¦ follow-through volume is everything ğŸ¢âš ï¸\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 14:19:26 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 2,
    "conversationId": "2025938554791043460",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025923307699114000",
    "text": "$IKT â€“ +30% premarket ğŸ‘€ğŸš€\nğŸ”¹ Core bull case: IKT-001 (imatinib prodrug) in PAH â€” lining up for a global pivotal Phase 3 (IMPROVE-PAH) ğŸ«ğŸ§¬\nğŸ”¹ Management has framed it as a single pivotal path that could pull forward the approval timeline â©\nğŸ”¹ Capital runway backdrop: theyâ€™ve been active on the financing front (raises/support to push the program) ğŸ’°\nğŸ”¹ Shares outstanding: ~136.78M ğŸ”¢\nğŸ”¹ Biotech tape = headline + momentumâ€¦ expect volatility ğŸ¢âš ï¸\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 13:18:51 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 0,
    "conversationId": "2025923307699114000",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025920318687027204",
    "text": "$SGN â€“ +30% premarket ğŸ‘€ğŸš€\nğŸ”¹ Catalyst: Form S-4 declared effective + March 13, 2026 special meeting to vote on the BlockchAIn business combination ğŸ—³ï¸ğŸ¤\nğŸ”¹ Marketâ€™s trading the â€œdeal closeâ€ momentum + crypto/AI narrative re-rate ğŸ§ âš¡ï¸\nğŸ”¹ Microcap mechanics: float-driven, headline-drivenâ€¦ expect whipsaws ğŸ¢âš ï¸\nğŸ”¹ Watch next: vote outcome + closing timeline + any financing/PIPE details ğŸ§¾ğŸ‘€\nFor informational purposes only â€“ not a buy/sell signal.",
    "createdAt": "Mon Feb 23 13:06:58 +0000 2026",
    "replyCount": 1,
    "retweetCount": 0,
    "likeCount": 1,
    "conversationId": "2025920318687027204",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025911323914113261",
    "text": "$EZRA â€“ +23% premarket ğŸ‘€ğŸš€\nğŸ”¹ Catalyst: definitive agreement to acquire a controlling stake in Enquantum (post-quantum cybersecurity) ğŸ”ğŸ¤–\nğŸ”¹ This is the new EZRA International playbook: tech control acquisitions + scale model ğŸ“ˆ\nğŸ”¹ Narrative: governments/enterprises rushing to â€œpost-quantum readyâ€ security = hot theme ğŸ§ âš¡ï¸\nğŸ”¹ Microcap mechanics matter: watch filings/financing + how the control stake is structured ğŸ§¾âš ï¸\nOpinions are my own. Not a solicitation to buy or sell.",
    "createdAt": "Mon Feb 23 12:31:13 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 2,
    "conversationId": "2025911323914113261",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  },
  {
    "id": "2025906935497695509",
    "text": "$BATL â€“ oil rebound + Iran headline risk = keep this on your radar ğŸ›¢ï¸ğŸŒğŸ‘€\nğŸ”¹ Low-float Delaware Basin E&P â€” when crude catches a bid, this can move FAST âš¡ï¸\nğŸ”¹ Ops catalyst: swapped gas-treating setup to a large-cap midstream partner â†’ improved flow + production momentum âœ…\nğŸ”¹ Deleveraging angle: selling West Quito Draw assets (~$62.6M) to pay down debt ğŸ§¾\nğŸ”¹ Shares outstanding: ~16.46M ğŸ”¢\nğŸ”¹ If oil keeps bouncing, buy-the-dip IMO â€” but expect violent swings ğŸ¢\nNot financial advice. For informational purposes only.",
    "createdAt": "Mon Feb 23 12:13:47 +0000 2026",
    "replyCount": 0,
    "retweetCount": 0,
    "likeCount": 3,
    "conversationId": "2025906935497695509",
    "author": {
      "username": "Bezel4455",
      "name": "Jon henson"
    },
    "authorId": "1521256895809753088"
  }
]
